Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Endocrine resistance, both primary and secondary, limits the effectiveness of standard breast cancer treatments like tamoxifen and aromatase inhibitors (AIs).
• Understanding the molecular mechanisms of endocrine resistance is crucial for developing new therapeutic strategies.
• Cotargeting the estrogen receptor (ER) with intracellular signaling pathways offers a promising approach to overcome resistance.

Purpose of the Study:

• To explore cotargeting strategies to overcome endocrine resistance in breast cancer.
• To evaluate the efficacy of combining endocrine therapy with inhibitors of proliferation and survival pathways.
• To identify potential therapeutic combinations for both first-line and second-line settings.

Main Methods:

• Review of preclinical evidence and clinical trial outcomes for combination therapies.
• Analysis of successes with mTOR antagonists (everolimus) and CDK4/6 inhibitors (palbociclib) in combination with endocrine agents.
• Evaluation of ongoing research into inhibitors of PI3K, Akt, HDAC, Src, IGFR-1, and FGFR.

Main Results:

• Combination therapy with everolimus and exemestane has shown success in secondary endocrine resistance.
• Addition of palbociclib to letrozole has demonstrated efficacy in the first-line setting.
• While growth factor inhibitors have yielded disappointing results, other cotargeting strategies are under investigation.

Conclusions:

• Cotargeting ER with specific signaling pathway inhibitors represents a viable strategy to enhance endocrine therapy efficacy in breast cancer.
• Future clinical trials require careful design, patient selection, and predictive biomarkers to maximize benefits.
• Combination therapies hold potential for improving outcomes in ER-positive breast cancer, particularly in overcoming endocrine resistance.